Ticker Symbol: TOS/TSX
Shares Outstanding: 58 785 682
QUEBEC CITY, Feb. 20, 2012 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings using ozone, today announced that it will report the Company's annual financial results ending December 31, 2011, on Wednesday, March 14, 2012. TSO3 will host a conference call at 10:30 A.M. (EST) the same day.
Analysts and institutional investors are invited to participate. The numbers to dial for access are 514 807-8791 (Montréal area), 416 644-3426 (Toronto area) or the toll-free number 1 800 731-5319. Other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3's Website at: www.tso3.com. The Webcast will be archived for 90 days.
TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solutions to other low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
For further information:
Source: TSO3 Inc.
Director - Investor and Business Relations
(418) 651-0003, Ext. 237
Email: [email protected]